Last reviewed · How we verify
Challenge: Control, irradiation
At a glance
| Generic name | Challenge: Control, irradiation |
|---|---|
| Sponsor | MC2 Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Start Taking Action For TB Diagnosis
- Autoimmune Basis for Postural Tachycardia Syndrome (NA)
- Trem-1 and Ultraviolet Radiation-induced Immune Suppression (EARLY_PHASE1)
- IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer (NA)
- LaseRF Trial: Radiofrequency Ablation vs. Laser Hemorrhoidoplasty for Hemorrhoidal Disease (NA)
- Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria (PHASE2)
- A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI (PHASE1)
- Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Challenge: Control, irradiation CI brief — competitive landscape report
- Challenge: Control, irradiation updates RSS · CI watch RSS
- MC2 Therapeutics portfolio CI